BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, January 16, 2026
Home » Topics » Briefs » Regulatory actions

Regulatory actions
Regulatory actions RSS Feed RSS

Regulatory actions for Sept. 25, 2025

Sep. 25, 2025
Regulatory snapshots, including global drug submissions and approvals, and other regulatory decisions and designations: Artios, Astrazeneca, Bioartic, Biogen, Cure Rare Disease, Daiichi Sankyo.
Read More

Regulatory actions for Sept. 24, 2025

Sep. 24, 2025
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Burning Rock, Fluid AI, Neuromod Devices, TSC Life.
Read More

Regulatory actions for Sept. 24, 2025

Sep. 24, 2025
Regulatory snapshots, including global drug submissions and approvals, and other regulatory decisions and designations: H. Lundbeck, Kelun-Biotech, Lexicon, Otsuka, Sanofi, Scholar Rock.
Read More

Regulatory actions for Sept. 23, 2025

Sep. 23, 2025
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Bunkerhill Health, Cionic, Heartflow, Noul.
Read More

Regulatory actions for Sept. 23, 2025

Sep. 23, 2025
Regulatory snapshots, including global drug submissions and approvals, and other regulatory decisions and designations: Astrazeneca, Alvotech, Amgen, Chiesi, Johnson & Johnson, Mavrix, Merck, Regeneron, Sanofi, Servier, Stealth.
Read More

Regulatory actions for Sept. 23, 2025

Sep. 23, 2025
Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific: Akeso, Alteogen, Alvotech, Biocon, Celltrion, Daiichi Sankyo, Eisai, Esperioin, Henlius, Innovent, Ipsen, Nuvation, Polyrizon, Verrica.
Read More

Regulatory actions for Sept. 22, 2025

Sep. 22, 2025
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Techsomed, Tempus.
Read More

Regulatory actions for Sept. 22, 2025

Sep. 22, 2025
Regulatory snapshots, including global drug submissions and approvals, and other regulatory decisions and designations: Alvotech, Ars, Celltrion, Esperion, Fuji, Henlius, Idorsia, Incyte, Innovent, Ionis, Ipsen, Johnson & Johnson, Kalvista, Merck, NS, Nuvation Bio, Polyrizon, Organon, Otsuka, Roche, Torii, Verrica.
Read More

Regulatory actions for Sept. 19, 2025

Sep. 19, 2025
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Kelyniam, Medtronic.
Read More

Regulatory actions for Sept. 19, 2025

Sep. 19, 2025
Regulatory snapshots, including global drug submissions and approvals, and other regulatory decisions and designations: Astrazeneca, Biogen, Curatis, Deciphera, J&D, Minovia, Replimune.
Read More
Previous 1 2 … 13 14 15 16 17 18 19 20 21 … 327 328 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 16, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 15, 2026.
  • SERPINB1 as potential biomarker for spinocerebellar ataxia type 2

    BioWorld Science
    Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
  • Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

    BioWorld
    With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
  • Businesswoman pressing dollar sign on touchscreen

    JPM 2026: Year kicks off with biopharma Q4 revenue and guidance

    BioWorld
    It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 Healthcare Conference with Alnylam...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing